Immune checkpoints PVR and PVRL2 are prognostic markers in AML and their blockade represents a new therapeutic option.
Stamm H, Klingler F, Grossjohann EM, Muschhammer J, Vettorazzi E, Heuser M, Mock U, Thol F, Vohwinkel G, Latuske E, Bokemeyer C, Kischel R, Dos Santos C, Stienen S, Friedrich M, Lutteropp M, Nagorsen D, Wellbrock J, Fiedler W.
Stamm H, et al. Among authors: vohwinkel g.
Oncogene. 2018 Sep;37(39):5269-5280. doi: 10.1038/s41388-018-0288-y. Epub 2018 May 31.
Oncogene. 2018.
PMID: 29855615
Free PMC article.